Article: Schering-Plough and Texas Biotechnology Form Alliance to Discover, Develop VLA-4 Antagonist Drugs to Treat Asthma.

MADISON, N.J. and HOUSTON, July 10 /PRNewswire/ --

Schering-Plough Corporation (NYSE: SGP) and Texas Biotechnology Corporation (Amex: TBC) today announced a worldwide research collaboration and license agreement to discover, develop and commercialize VLA-4 antagonists. VLA-4 antagonists represent a new class of compounds that has shown promise in multiple preclinical animal models of asthma. The primary focus of the collaboration will be to discover orally available VLA-4 antagonists as treatments for asthma.

Richard Dixon, Ph.D., chief scientific officer and senior vice president of research, Texas Biotechnology, stated, "We believe the mechanism of ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!